Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has granted 34,550 restricted stock units (RSUs) to two new employees. The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment. Vesting is contingent upon continued employment with Solid Biosciences through each vesting date.
Solid Biosciences (NASDAQ: SLDB), un'azienda nel settore delle scienze della vita specializzata in terapie genetiche di precisione per malattie neuromuscolari e cardiache, ha assegnato 34.550 unit脿 azionarie vincolate (RSU) a due nuovi dipendenti. Le RSU matureranno in un arco di quattro anni, con il 25% che si consolida ogni anno nell'anniversario della data di assegnazione. Le assegnazioni sono state effettuate nell'ambito del Piano di Incentivazione Azionaria 2024 della Societ脿 e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4), servendo come incentivo all'assunzione. La maturazione 猫 subordinata alla continuazione del rapporto di lavoro con Solid Biosciences fino a ciascuna data di maturazione.
Solid Biosciences (NASDAQ: SLDB), una empresa de ciencias de la vida centrada en medicamentos gen茅ticos de precisi贸n para enfermedades neuromusculares y card铆acas, ha otorgado 34,550 unidades restringidas de acciones (RSUs) a dos nuevos empleados. Las RSUs se consolidar谩n durante cuatro a帽os, con un 25% consolid谩ndose anualmente en cada aniversario de la fecha de concesi贸n. Las concesiones se emitieron bajo el Plan de Incentivos de Acciones por Inducci贸n 2024 de la Compa帽铆a y cumplen con la Regla de Cotizaci贸n Nasdaq 5635(c)(4), sirviendo como incentivo para el empleo. La consolidaci贸n est谩 condicionada a la continuidad del empleo con Solid Biosciences hasta cada fecha de consolidaci贸n.
Solid Biosciences (NASDAQ : SLDB), une soci茅t茅 des sciences de la vie sp茅cialis茅e dans les m茅dicaments g茅n茅tiques de pr茅cision pour les maladies neuromusculaires et cardiaques, a attribu茅 34 550 unit茅s d'actions restreintes (RSU) 脿 deux nouveaux employ茅s. Les RSU seront acquises sur une p茅riode de quatre ans, avec 25 % qui seront acquis chaque ann茅e 脿 l'anniversaire de la date d'attribution. Les attributions ont 茅t茅 effectu茅es dans le cadre du Plan d'Incitation 脿 l'Attribution d'Actions 2024 de la soci茅t茅 et sont conformes 脿 la r猫gle de cotation Nasdaq 5635(c)(4), servant d'incitation 脿 l'embauche. L'acquisition est conditionn茅e 脿 la poursuite de l'emploi chez Solid Biosciences jusqu'脿 chaque date d'acquisition.
Solid Biosciences (NASDAQ: SLDB), ein Life-Sciences-Unternehmen, das sich auf pr盲zise genetische Therapien f眉r neuromuskul盲re und kardiale Erkrankungen spezialisiert hat, hat zwei neuen Mitarbeitern 34.550 Restricted Stock Units (RSUs) gew盲hrt. Die RSUs werden 眉ber vier Jahre unverfallbar, wobei j盲hrlich jeweils 25 % am Jahrestag des Zuteilungsdatums unverfallbar werden. Die Zuteilungen erfolgten im Rahmen des Inducement Stock Incentive Plans 2024 des Unternehmens und entsprechen der Nasdaq-Listing-Regel 5635(c)(4), dienen also als Anreiz f眉r die Einstellung. Die Unverfallbarkeit ist an die fortgesetzte Besch盲ftigung bei Solid Biosciences bis zu jedem Unverfallbarkeitstermin gebunden.
Positive
None.
Negative
None.
CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.聽(Nasdaq: SLDB) (the 鈥淐ompany鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (鈥淩SUs鈥�) to two newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee鈥檚 continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company鈥檚 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee鈥檚 acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About聽Solid Biosciences Solid Biosciences聽is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich鈥檚 ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid鈥檚 mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit聽.
Solid Biosciences Investor Contact: Nicole Anderson Director, Investor Relations and Corporate Communications Solid Biosciences Inc.
Media Contact: Glenn Silver FINN Partners
FAQ
What type of RSUs did Solid Biosciences (SLDB) grant to new employees in June 2025?
Solid Biosciences granted 34,550 restricted stock units that vest in four equal annual installments over four years to two newly hired employees.
How does the vesting schedule work for Solid Biosciences' June 2025 RSU grants?
The RSUs vest in four equal installments, with 25% vesting on each anniversary of the grant date until the fourth anniversary.
What is the purpose of Solid Biosciences' 2024 Inducement Stock Incentive Plan?
The plan is designed to provide equity incentives as material inducement for new employees to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
What happens to the RSUs if an employee leaves Solid Biosciences?
The RSUs only vest if the employee maintains continued service with the company through each applicable vesting date.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
